Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582591 | 0.95 | HTR2A (0.53) | HSD11B1SMN1; SMN2LMNAHTTHTR2A | |
| SCHEMBL1582543 | 0.90 | MGLL (0.57) | HSD11B1SMN1; SMN2LMNAHTTHTR2A | |
| SCHEMBL1582856 | 0.89 | HSD11B1 (0.54) | HSD11B1SMN1; SMN2LMNAHTR2AHTR2C | |
| SCHEMBL1582751 | 0.89 | HSD11B1 (0.47) | HSD11B1SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL1582967 | 0.88 | HSD11B1 (0.58) | HSD11B1SMN1; SMN2LMNAHTTHTR2A | |
| SCHEMBL1582908 | 0.86 | HSD11B1 (0.60) | HSD11B1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL1582289 | 0.85 | HSD11B1 (0.53) | HSD11B1SMN1; SMN2LMNAHTTHTR2A | |
| SCHEMBL1582358 | 0.84 | HTR2A (0.46) | HSD11B1SMN1; SMN2LMNAHTR2AHTR2C | |
| SCHEMBL1582920 | 0.84 | HSD11B1 (0.51) | HSD11B1SMN1; SMN2LMNAHTTHTR2A | |
| SCHEMBL1582926 | 0.82 | HSD11B1 (0.53) | HSD11B1HTR2AHTR2CHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546100-B1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK HOLDINGS CO LTD (KR) | 2011-04-20 | — | — | EP | disclosed |
| EP-1546100-B1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK HOLDINGS CO LTD (KR) | 2011-04-20 | — | — | EP | disclosed |
| US-6770659-B2 | Benzoyl piperidine compounds | SK CORPORATION (KR) | 2004-08-03 | — | — | US | disclosed |
| WO-2004018423-A1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK CORPORATION (KR) | 2004-03-04 | — | — | WO | disclosed |
| US-20040044033-A1 | New benzoyl piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044033-A1 | New benzoyl piperidine compounds | GABRE, GRIN2C, GRIN1 | HSD11B1 2872/4885SMN1; SMN2 133/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.